Bharat Biotech submits new request to Brazilian regulator on GMP issues for Covaxin


PTI, May 27, 2021, 10:35 AM IST

Hyderabad: Bharat Biotech which faced a red flag from Brazil’s health regulator for supply of COVID-19 vaccine Covaxin to that country over the issues of Good Manufacturing Practices in its plant, has filed a new request to the Brazilian authorities for certification.

According to the National Health Surveillance Agency of Brazil Anvisa, Bharat Biotech made the request on May 25 and a day before the Ministry of Health of the South American country filed a new application for authorisation to import 20 million doses of the Covaxin.

Earlier, Anvisa denied permission to import Covaxin after its authorities found that the plant in which the jab is being made did not meet the Good Manufacturing Practice (GMP) requirements.

“Regarding the fulfillment of Good Manufacturing Practices by the manufacturer Bharat Biotech, one of the main aspects that motivated the previous decision, the company filed a new certification request at Anvisa, referring to the production line of the finished product…Complementing the previous information, a new request for certification of Good Manufacturing Practices for the biological input produced by Bharat Biotech was filed on Tuesday,” Anvisa said in a roughly translated Portuguese.

BharatBiotechInternational Limited on February 26 said it has signed an agreement with theBraziliangovernment for supply of 20 million doses of Covaxin during the second and third quarters of the current year.

However, the Brazilian health regulator refused to import the vaccine into the country citing GMP issues.

The vaccine maker had earlier told P T I that the requirements pointed out during inspection will be fulfilled, the timelines for fulfillment “is under discussion with theBrazilNRA and will be resolved soon.”

GMP certification of all stages of vaccine production is a prerequisite for the registration of the immunizer in Brazil.

For the exceptional import order, only the minimum data of Good Production Practices are analyzed, but without the need for the certificate in question, Anvisa further said.

Anvisa recently authorised the conduct of clinical trials of Covaxin in Brazil.

Approval for tests on the immuniser developed in India will serve to assess the efficacy, safety and consistency between vaccine batches, it said.

The study which was requested by Precis Farmacutica, representative in Brazil for Bharat Biotech involves the application of two doses, 28 days apart, in 4,500 volunteers, in the states of So Paulo, Rio de Janeiro, Bahia and Mato Grosso in Brazil.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Vehicle from CM’s convoy hits another in south Mumbai

Heavy rains: Schools, colleges of DK, Udupi to remain close on Wed

1984 riots case: HC stays order granting bail to Sajjan Kumar, seeks response on SIT plea

Twitter challenges govt blocking order before Karnataka High Court

Flights diverted due to heavy rains in Mangaluru

Heavy rains: Kodagu DC declares holiday to schools, colleges on Wed

Karnataka: State BJP hopeful of wresting Hassan district from JD(S)


Related Articles More

Vehicle from CM’s convoy hits another in south Mumbai

1984 riots case: HC stays order granting bail to Sajjan Kumar, seeks response on SIT plea

Fresh plea in SC challenging government’s Agnipath scheme

Talks to convert Delhi into full UT, alleges Kejriwal; says move will face stiff resistance

‘Casinos over common people’: Cong slams govt on GST changes

MUST WATCH

Chandrashekhar guruji case : accused arrested

NEWS BULLETIN 05-07-2022

Heavy Rain : Huge Rock fall in road at madikeri

Land Slide Karnataka Kerala Road Close

Sarala vaastu fame Dr Chandrashekhar guruju killed in Hubballi


Latest Additions

Vehicle from CM’s convoy hits another in south Mumbai

Heavy rains: Schools, colleges of DK, Udupi to remain close on Wed

Heavy rains continue to wreak havoc in coast

1984 riots case: HC stays order granting bail to Sajjan Kumar, seeks response on SIT plea

Fresh plea in SC challenging government’s Agnipath scheme

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.